5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ligand-dependent protein degradation has emerged as a compelling strategy to pharmacologically control the protein content of cells. So far, however, only a limited number of E3 ligases have been found to support this process. Here, we use a chemical proteomic strategy that leverages broadly reactive, cysteine-directed electrophilic fragments coupled to selective ligands for intracellular proteins (e.g., SLF for FKBP12, JQ1 for BRD4) to screen for heterobifunctional degrader compounds (or PROTACs) that operate by covalent adduction of E3 ligases. This approach identified DCAF16 – a poorly characterized substrate recognition component of CUL4-DDB1 E3 ubiquitin ligases – as a target of electrophilic PROTACs that promote the nuclear-restricted degradation of proteins. We find that only a modest fraction (~10-40%) of DCAF16 needs to be modified to support protein degradation, pointing to the potential for electrophilic PROTACs to induce neo-substrate degradation without substantially perturbing the function of the participating E3 ligase.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.

          The intracellular levels of many proteins are regulated by ubiquitin-dependent proteolysis. One of the best-characterized enzymes that catalyzes the attachment of ubiquitin to proteins is a ubiquitin ligase complex, Skp1-Cullin-F box complex containing Hrt1 (SCF). We sought to artificially target a protein to the SCF complex for ubiquitination and degradation. To this end, we tested methionine aminopeptidase-2 (MetAP-2), which covalently binds the angiogenesis inhibitor ovalicin. A chimeric compound, protein-targeting chimeric molecule 1 (Protac-1), was synthesized to recruit MetAP-2 to SCF. One domain of Protac-1 contains the I kappa B alpha phosphopeptide that is recognized by the F-box protein beta-TRCP, whereas the other domain is composed of ovalicin. We show that MetAP-2 can be tethered to SCF(beta-TRCP), ubiquitinated, and degraded in a Protac-1-dependent manner. In the future, this approach may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Induced protein degradation: an emerging drug discovery paradigm

            Small-molecule drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function. This article discusses emerging technologies, such as proteolysis-targeting chimaeras (PROTACs), that exploit cellular quality control machinery to selectively degrade target proteins, which could have advantages over traditional approaches, including the potential to target proteins that are not currently therapeutically tractable.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Catalytic in vivo protein knockdown by small-molecule PROTACs.

              The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clinical benefit. This strategy, however, generally requires excessive drug concentrations to ensure sufficient occupancy, often leading to adverse side effects. Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chemical knockdown strategy in which a heterobifunctional molecule recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degradation. These compounds behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equilibrium occupancy. We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concentrations. In addition, mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts. Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-molecule agents with the potent protein knockdown of RNAi and CRISPR.
                Bookmark

                Author and article information

                Journal
                101231976
                32624
                Nat Chem Biol
                Nat. Chem. Biol.
                Nature chemical biology
                1552-4450
                1552-4469
                27 March 2019
                17 June 2019
                July 2019
                17 December 2019
                : 15
                : 7
                : 737-746
                Affiliations
                The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92307
                Author notes
                [* ]To whom correspondence should be addressed: zhangx@ 123456scripps.edu , cravatt@ 123456scripps.edu

                Author contributions.

                X.Z. and B.F.C. conceived of the research and wrote the paper. X.Z. developed methods, performed experiments, and analyzed data. X.Z. and M.M.D. analyzed chemical proteomic data. X.Z. designed and synthesized KB02-SLF, KB02-PEG0-SLF, KB02-PEG4-SLF, KB03-SLF, KB05-SLF and C-KB02-SLF. V.M.C. designed and synthesized KB02-JQ1. T.G.W. designed and synthesized lenalidomide-SLF. V.M.C. characterized all the compounds.

                Article
                NIHMS1525330
                10.1038/s41589-019-0279-5
                6592777
                31209349
                5796deb4-9130-4e17-9a5d-91e6f74ad5e7

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Biochemistry
                Biochemistry

                Comments

                Comment on this article